The macular degeneration treatment ‘Vabysmo’ is expected to be listed for reimbursement in October this year.

According to industry sources, Roche Korea has completed drug pricing negotiations for its bispecific antibody Vabysmo (faricimab) with the National Health Insurance Service. Once it passes the Health Insurance Policy Review Committee, reimbursement can immediately be applied to the drug.

Vabysmo, which was approved in Korea in January this year, passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review in July, then immediately entered into drug price negotiations and virtually completed the reimbursement process within 8 mont